FDA Grants Accelerated Approval to Camizestrant for ESR1-Mutant HR-Positive/HER2-Negative Breast Cancer, Four Months After Advisers Voted No
核心洞察
The FDA granted accelerated approval to camizestrant (Etcamah (搜索)) with a CDK4/6 inhibitor (搜索) for HR-positive, HER2-negative advanced breast cancer with emerging ESR1 (搜索) mutations.
Approval followed the Oncologic Drugs Advisory Committee's 6-3 vote against the application in April, with the agency reviewing supplemental AstraZeneca analyses before deciding.
In the SERENA-6 trial of 315 patients, median progression-free survival was 16 months with camizestrant versus 9.2 months on continued standard therapy, hazard ratio 0.44.
The FDA on September 4 granted accelerated approval to camizestrant, sold as Etcamah (搜索), in combination with a CDK4/6 inhibitor (搜索) for adults with hormone receptor-positive, HER2-negative advanced breast cancer whose tumors develop an ESR1 (搜索) mutation during first-line therapy. The agency simultaneously approved the Guardant360 CDx (搜索) blood test as the companion diagnostic, allowing the resistance mutation to be identified through circulating tumor DNA rather than imaging.
The decision reversed the judgment of the agency's own Oncologic Drugs Advisory Committee, which voted six to three against the application on April 30, concluding that the data available at that time did not demonstrate a clinically meaningful benefit for patients whose ESR1 (搜索) mutations were detected by blood test before any disease progression appeared on a scan. The FDA postponed its decision in May to review supplemental analyses submitted by AstraZeneca ahead of updated results presented at the American Society of Clinical Oncology annual meeting. Advisory committee votes are not binding, and the agency departs from them periodically.
The Resistance Mutation and the Trial Behind the Approval
In its announcement, the FDA described ESR1 (搜索) as an acquired resistance mutation carried by fewer than 5 percent of patients at metastatic diagnosis but developed by nearly 40 percent after progressing on an aromatase inhibitor (搜索). These tumors are typically treated with drugs that cut off the tumor's estrogen supply, but the ESR1 change allows cancer cells to keep growing.
The approval rests on SERENA-6, a randomized, double-blind, placebo-controlled trial of 315 patients who had already been receiving an aromatase inhibitor (搜索) plus a CDK4/6 inhibitor (搜索) for at least six months with no evidence of progression. Blood testing identified an emerging ESR1 (搜索) mutation, and patients were randomly assigned either to switch to camizestrant or to continue their existing regimen.
In the analysis described in the approval summary published by The ASCO Post, median progression-free survival was 16 months in the camizestrant group versus 9.2 months in the comparison group, with a hazard ratio of 0.44. Overall survival data were not mature at that analysis.
Supplemental data extended the picture. At a third data cutoff with median follow-up of 23.5 months, median progression-free survival reached 16.8 months versus 9.2 months, according to updated trial results reported by CancerNetwork. A prespecified secondary endpoint measuring time to second progression or death reached statistical significance at 25.7 months versus 19.1 months, and the early switch delayed the need for chemotherapy or antibody-drug conjugate therapy by a median of 3.9 months.
Why the Second Progression Endpoint Mattered
The committee's objection was not about whether the drug works, but whether acting on a blood test result before a patient has any sign of worsening disease produces a benefit that matters to the patient. A committee concerned that delaying first progression might simply move the problem downstream would want evidence that the benefit survives past that point, and the second progression analysis provided it.
Dr. Donna McNamara, a breast medical oncologist at the John Theurer Cancer Center at Hackensack University Medical Center, told Newsweek the approval is a "transformative shift" for patients because it introduces a "proactive, rather than reactive, treatment model."
"For the first time, doctors can use a specialized companion blood test to detect an ESR1 (搜索) mutation—an early indicator that the cancer is developing resistance to standard hormone therapy—before any tumor growth actually appears on an imaging scan," she said, calling it a "massively positive leap forward for precision oncology."
McNamara also noted caveats inherent to accelerated approval. "Regulators are still waiting on mature data to determine if this early-switch strategy actually helps patients live longer overall (overall survival), rather than simply delaying immediate progression," she said, adding that potential serious side effects including heart arrhythmia mean doctors and patients must "carefully monitor and weigh these risks against the groundbreaking benefits of this proactive new approach."
Dave Fredrickson of AstraZeneca said in a statement that the Etcamah (搜索) combination is a "new approach using circulating tumor DNA and is the first and only medicine of its type in the 1st-line setting."
Safety Profile and Dosing
The prescribing information carries a boxed warning for the risk of arrhythmia from QTc interval prolongation when camizestrant is taken alongside other drugs that prolong the QTc interval, plus warnings for slowed heart rate and fetal harm. Many common medications affect the QTc interval, including certain antibiotics, anti-nausea drugs and antidepressants.
Grade 3 or higher side effects were more frequent with camizestrant than with continued standard therapy, at 60 percent versus 46 percent, driven mainly by low white blood cell counts. The recommended dose is 75 milligrams taken orally once daily, with the CDK4/6 inhibitor (搜索) continued at the same dose.
Access Hinges on Molecular Monitoring
The practical bottleneck for patients is not the pill but the monitoring that identifies the mutation. The approval applies only when an ESR1 (搜索) mutation is detected by an authorized blood test during first-line treatment, meaning a patient whose practice does not perform serial circulating tumor DNA testing will not be identified as eligible regardless of whether the mutation is present. That creates a two-tier situation between practices that have adopted routine molecular monitoring and those that have not, a divide that often tracks with academic centers versus smaller community practices.
Insurers vary in how they cover serial molecular testing, and a denial can often be appealed with documentation from the treating physician. Manufacturer patient assistance programs and independent copay foundations exist for both the drug and the assay.
Camizestrant is already approved in the European Union under the same brand name, as noted in AstraZeneca's statement on the approval.
Open Questions
Several issues remain unresolved. Overall survival results are not final, the confirmatory trial requirement has not been publicly detailed, and it is not yet clear how quickly insurers will cover serial ctDNA monitoring in community settings. The agency's announcement of the approval did not address the earlier committee vote. Patients currently on first-line therapy do not need to change anything based on this news, but the approval is worth raising at the next appointment.